Journal of Shanghai Jiao Tong University (Medical Science) ›› 2024, Vol. 44 ›› Issue (4): 462-468.doi: 10.3969/j.issn.1674-8115.2024.04.006
• Clinical research • Previous Articles
HAO Mingxiu(
), CHEN Hongwei(), WANG Junlin, TANG Yinhan, WU Yunyun, JIN Yuhua, HU Yaomin()
Received:2023-09-25
Accepted:2024-03-04
Online:2024-04-28
Published:2024-04-28
Contact:
HU Yaomin
E-mail:haomingxiu@renji.com;chw13026736003@163.com;amin99@163.com
Supported by:CLC Number:
HAO Mingxiu, CHEN Hongwei, WANG Junlin, TANG Yinhan, WU Yunyun, JIN Yuhua, HU Yaomin. Investigation and epidemiological analysis of chronic diseases and comorbidities in hospitalized patients[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 462-468.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2024.04.006
| Variable | Total (n=2 045) | Female (n=771) | Male (n=1 274) | P value |
|---|---|---|---|---|
| Age/year | 61.5±15.2 | 60.7±15.3 | 62.0±15.0 | 0.057 |
| Age range/n(%) | 0.173 | |||
| 30‒39 years | 114 (5.57) | 56 (7.26) | 58 (4.55) | |
| 40‒49 years | 362 (17.70) | 136 (17.64) | 226 (17.74) | |
| 50‒59 years | 568 (27.78) | 213 (27.63) | 355 (27.86) | |
| 60‒69 years | 370 (18.09) | 135 (17.51) | 235 (18.45) | |
| 70‒79 years | 332 (16.23) | 128 (16.60) | 204 (16.01) | |
| 80‒89 years | 209 (10.22) | 76 (9.86) | 133 (10.44) | |
| 90‒99 years | 90 (4.40) | 27 (3.50) | 63 (4.95) | |
| Hypertension/n(%) | 809 (43.68) | 235 (34.46) | 574 (49.06) | 0.000 |
| Diabetes mellitus/n(%) | 457 (24.81) | 113 (16.64) | 344 (29.58) | 0.000 |
| Hyperlipidemia/n(%) | 330 (18.38) | 107 (16.24) | 223 (19.63) | 0.074 |
| Coronary artery disease/n(%) | 213 (11.99) | 46 (7.01) | 167 (14.90) | 0.000 |
| Stroke/n(%) | 164 (9.29) | 41 (6.26) | 123 (11.08) | 0.000 |
| COPD/n(%) | 52 (2.96) | 4 (0.61) | 48 (4.35) | 0.000 |
| CKD/n(%) | 98 (5.56) | 24 (3.67) | 74 (6.67) | 0.008 |
| Malignant tumor/n(%) | 384 (21.48) | 140 (20.99) | 244 (21.77) | 0.704 |
| Thyroid nodule/n(%) | 452 (25.87) | 169 (26.45) | 283 (25.54) | 0.681 |
| Hyperthyroidism/n(%) | 20 (1.13) | 6 (0.92) | 14 (1.26) | 0.512 |
| Hypothyroidism/n(%) | 75 (4.24) | 43 (6.52) | 32 (2.89) | 0.000 |
| Rheumatic disease/n(%) | 35 (2.00) | 16 (2.45) | 19 (1.73) | 0.302 |
| Anxiety/depression/n(%) | 39 (2.22) | 13 (1.98) | 26 (2.36) | 0.673 |
Tab 1 Characteristics of the population and comparison between male and female patients
| Variable | Total (n=2 045) | Female (n=771) | Male (n=1 274) | P value |
|---|---|---|---|---|
| Age/year | 61.5±15.2 | 60.7±15.3 | 62.0±15.0 | 0.057 |
| Age range/n(%) | 0.173 | |||
| 30‒39 years | 114 (5.57) | 56 (7.26) | 58 (4.55) | |
| 40‒49 years | 362 (17.70) | 136 (17.64) | 226 (17.74) | |
| 50‒59 years | 568 (27.78) | 213 (27.63) | 355 (27.86) | |
| 60‒69 years | 370 (18.09) | 135 (17.51) | 235 (18.45) | |
| 70‒79 years | 332 (16.23) | 128 (16.60) | 204 (16.01) | |
| 80‒89 years | 209 (10.22) | 76 (9.86) | 133 (10.44) | |
| 90‒99 years | 90 (4.40) | 27 (3.50) | 63 (4.95) | |
| Hypertension/n(%) | 809 (43.68) | 235 (34.46) | 574 (49.06) | 0.000 |
| Diabetes mellitus/n(%) | 457 (24.81) | 113 (16.64) | 344 (29.58) | 0.000 |
| Hyperlipidemia/n(%) | 330 (18.38) | 107 (16.24) | 223 (19.63) | 0.074 |
| Coronary artery disease/n(%) | 213 (11.99) | 46 (7.01) | 167 (14.90) | 0.000 |
| Stroke/n(%) | 164 (9.29) | 41 (6.26) | 123 (11.08) | 0.000 |
| COPD/n(%) | 52 (2.96) | 4 (0.61) | 48 (4.35) | 0.000 |
| CKD/n(%) | 98 (5.56) | 24 (3.67) | 74 (6.67) | 0.008 |
| Malignant tumor/n(%) | 384 (21.48) | 140 (20.99) | 244 (21.77) | 0.704 |
| Thyroid nodule/n(%) | 452 (25.87) | 169 (26.45) | 283 (25.54) | 0.681 |
| Hyperthyroidism/n(%) | 20 (1.13) | 6 (0.92) | 14 (1.26) | 0.512 |
| Hypothyroidism/n(%) | 75 (4.24) | 43 (6.52) | 32 (2.89) | 0.000 |
| Rheumatic disease/n(%) | 35 (2.00) | 16 (2.45) | 19 (1.73) | 0.302 |
| Anxiety/depression/n(%) | 39 (2.22) | 13 (1.98) | 26 (2.36) | 0.673 |
Fig 1 Distributions of comorbidities of the study population
| Variable | Number of comorbidities | P value | ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | ≥6 | ||
| Age/n(%) | 0.000 | |||||||
| 30‒39 years | 1 (12.5) | 12 (12.12) | 5 (5.10) | 19 (13.77) | 13 (7.56) | 19 (8.6) | 25 (2.26) | |
| 40‒49 years | 3 (37.5) | 14 (14.14) | 23 (23.47) | 35 (25.36) | 48 (27.91) | 57 (25.79) | 162 (14.63) | |
| 50‒59 years | 3 (37.5) | 38 (38.38) | 40 (40.82) | 43 (31.16) | 52 (30.23) | 62 (28.05) | 298 (26.92) | |
| 60‒69 years | 1 (12.5) | 15 (15.15) | 19 (19.39) | 20 (14.49) | 24 (13.95) | 38 (17.19) | 199 (17.98) | |
| 70‒79 years | 0 (0) | 16 (16.16) | 9 (9.18) | 19 (13.77) | 21 (12.21) | 15 (6.79) | 207 (18.70) | |
| 80‒89 years | 0 (0) | 2 (2.02) | 1 (1.02) | 2 (1.45) | 11 (6.40) | 29 (13.12) | 142 (12.83) | |
| 90‒99 years | 0 (0) | 2 (1.01) | 1 (1.02) | 0 (0) | 3 (1.74) | 1 (0.45) | 74 (6.68) | |
| Gender/n(%) | 0.043 | |||||||
| Female | 4 (50.0) | 44 (44.44) | 29 (29.59) | 45 (32.61) | 78 (45.35) | 87 (39.37) | 390 (35.23) | |
| Male | 4 (50.0) | 55 (55.56) | 69 (70.41) | 93 (67.39) | 94 (54.65) | 134 (60.63) | 717 (64.77) | |
Tab 2 Trends of comorbidities on different genders and age groups
| Variable | Number of comorbidities | P value | ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | ≥6 | ||
| Age/n(%) | 0.000 | |||||||
| 30‒39 years | 1 (12.5) | 12 (12.12) | 5 (5.10) | 19 (13.77) | 13 (7.56) | 19 (8.6) | 25 (2.26) | |
| 40‒49 years | 3 (37.5) | 14 (14.14) | 23 (23.47) | 35 (25.36) | 48 (27.91) | 57 (25.79) | 162 (14.63) | |
| 50‒59 years | 3 (37.5) | 38 (38.38) | 40 (40.82) | 43 (31.16) | 52 (30.23) | 62 (28.05) | 298 (26.92) | |
| 60‒69 years | 1 (12.5) | 15 (15.15) | 19 (19.39) | 20 (14.49) | 24 (13.95) | 38 (17.19) | 199 (17.98) | |
| 70‒79 years | 0 (0) | 16 (16.16) | 9 (9.18) | 19 (13.77) | 21 (12.21) | 15 (6.79) | 207 (18.70) | |
| 80‒89 years | 0 (0) | 2 (2.02) | 1 (1.02) | 2 (1.45) | 11 (6.40) | 29 (13.12) | 142 (12.83) | |
| 90‒99 years | 0 (0) | 2 (1.01) | 1 (1.02) | 0 (0) | 3 (1.74) | 1 (0.45) | 74 (6.68) | |
| Gender/n(%) | 0.043 | |||||||
| Female | 4 (50.0) | 44 (44.44) | 29 (29.59) | 45 (32.61) | 78 (45.35) | 87 (39.37) | 390 (35.23) | |
| Male | 4 (50.0) | 55 (55.56) | 69 (70.41) | 93 (67.39) | 94 (54.65) | 134 (60.63) | 717 (64.77) | |
| Variable | Age group | P for trend | ||||||
|---|---|---|---|---|---|---|---|---|
| 30‒39 years | 40‒49 years | 50‒59 years | 60‒69 years | 70‒79 years | 80‒89 years | 90‒99 years | ||
| Hypertension/n(%) | 10 (11.49) | 77 (24.06) | 175 (34.25) | 158 (47.59) | 176 (57.14) | 148 (71.84) | 65 (73.86) | 0.000 |
| Diabetes mellitus/n(%) | 15 (15.63) | 37 (11.60) | 89 (17.62) | 95 (28.27) | 102 (33.89) | 87 (43.50) | 32 (37.65) | 0.000 |
| Hyperlipidemia/n(%) | 15 (16.30) | 71 (22.12) | 103 (20.52) | 56 (17.55) | 48 (16.61) | 27 (13.92) | 10 (12.82) | 0.010 |
| Coronary artery disease/n(%) | 0 (0) | 7 (2.28) | 34 (6.92) | 44 (13.88) | 39 (13.3) | 54 (27.14) | 35 (41.67) | 0.000 |
| Stroke/n(%) | 0 (0) | 2 (0.65) | 11 (2.25) | 19 (6.05) | 25 (8.68) | 65 (32.83) | 42 (50.0) | 0.000 |
| COPD/n(%) | 0 (0) | 0 (0) | 2 (0.41) | 5 (1.60) | 16 (5.59) | 13 (6.60) | 16 (19.51) | 0.000 |
| CKD/n(%) | 0 (0) | 3 (0.98) | 4 (0.82) | 6 (1.92) | 18 (6.25) | 37 (18.69) | 30 (35.71) | 0.000 |
| Malignant tumor/n(%) | 15 (17.24) | 30 (9.84) | 79 (15.86) | 72 (22.50) | 102 (34.69) | 63 (31.50) | 23 (27.38) | 0.000 |
| Rheumatic disease/n(%) | 1 (1.16) | 2 (0.66) | 5 (1.02) | 8 (2.56) | 12 (4.20) | 4 (2.12) | 3 (3.70) | 0.002 |
| Anxiety/depression/n(%) | 2 (2.30) | 1 (0.33) | 3 (0.61) | 8 (2.56) | 9 (3.11) | 9 (4.62) | 7 (8.33) | 0.000 |
Tab 3 Trend of prevalence of common chronic diseases with age
| Variable | Age group | P for trend | ||||||
|---|---|---|---|---|---|---|---|---|
| 30‒39 years | 40‒49 years | 50‒59 years | 60‒69 years | 70‒79 years | 80‒89 years | 90‒99 years | ||
| Hypertension/n(%) | 10 (11.49) | 77 (24.06) | 175 (34.25) | 158 (47.59) | 176 (57.14) | 148 (71.84) | 65 (73.86) | 0.000 |
| Diabetes mellitus/n(%) | 15 (15.63) | 37 (11.60) | 89 (17.62) | 95 (28.27) | 102 (33.89) | 87 (43.50) | 32 (37.65) | 0.000 |
| Hyperlipidemia/n(%) | 15 (16.30) | 71 (22.12) | 103 (20.52) | 56 (17.55) | 48 (16.61) | 27 (13.92) | 10 (12.82) | 0.010 |
| Coronary artery disease/n(%) | 0 (0) | 7 (2.28) | 34 (6.92) | 44 (13.88) | 39 (13.3) | 54 (27.14) | 35 (41.67) | 0.000 |
| Stroke/n(%) | 0 (0) | 2 (0.65) | 11 (2.25) | 19 (6.05) | 25 (8.68) | 65 (32.83) | 42 (50.0) | 0.000 |
| COPD/n(%) | 0 (0) | 0 (0) | 2 (0.41) | 5 (1.60) | 16 (5.59) | 13 (6.60) | 16 (19.51) | 0.000 |
| CKD/n(%) | 0 (0) | 3 (0.98) | 4 (0.82) | 6 (1.92) | 18 (6.25) | 37 (18.69) | 30 (35.71) | 0.000 |
| Malignant tumor/n(%) | 15 (17.24) | 30 (9.84) | 79 (15.86) | 72 (22.50) | 102 (34.69) | 63 (31.50) | 23 (27.38) | 0.000 |
| Rheumatic disease/n(%) | 1 (1.16) | 2 (0.66) | 5 (1.02) | 8 (2.56) | 12 (4.20) | 4 (2.12) | 3 (3.70) | 0.002 |
| Anxiety/depression/n(%) | 2 (2.30) | 1 (0.33) | 3 (0.61) | 8 (2.56) | 9 (3.11) | 9 (4.62) | 7 (8.33) | 0.000 |
| Variable | Diabetes mellitus | Hyperlipidemia | Coronary artery disease | Stroke | COPD | CKD | Malignant tumor | Rheumatic disease | Anxiety/ depression |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | 0.35① | 0.11① | 0.27① | 0.23① | 0.06① | 0.18① | 0.02 | 0.04 | 0.07① |
| Diabetes mellitus | 0.06① | 0.24① | 0.20① | 0.01 | 0.19① | 0.06① | 0.06① | -0.01 | |
| Hyperlipidemia | 0.11① | 0.10 | -0.02 | 0.08 | -0.06① | -0.02 | -0.01 | ||
| Coronary artery disease | 0.21① | 0.10① | 0.19① | 0.01 | 0.004 | 0.10① | |||
| Stroke | 0.13① | 0.29① | -0.004 | 0.03 | 0.15① | ||||
| COPD | 0.11① | 0.04 | 0.03 | 0.07① | |||||
| CKD | 0.04 | 0.04 | 0.05① | ||||||
| Malignant tumor | -0.02 | 0.05① | |||||||
| Rheumatic disease | 0.04 |
Tab 4 Correlation among common chronic diseases （r）
| Variable | Diabetes mellitus | Hyperlipidemia | Coronary artery disease | Stroke | COPD | CKD | Malignant tumor | Rheumatic disease | Anxiety/ depression |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | 0.35① | 0.11① | 0.27① | 0.23① | 0.06① | 0.18① | 0.02 | 0.04 | 0.07① |
| Diabetes mellitus | 0.06① | 0.24① | 0.20① | 0.01 | 0.19① | 0.06① | 0.06① | -0.01 | |
| Hyperlipidemia | 0.11① | 0.10 | -0.02 | 0.08 | -0.06① | -0.02 | -0.01 | ||
| Coronary artery disease | 0.21① | 0.10① | 0.19① | 0.01 | 0.004 | 0.10① | |||
| Stroke | 0.13① | 0.29① | -0.004 | 0.03 | 0.15① | ||||
| COPD | 0.11① | 0.04 | 0.03 | 0.07① | |||||
| CKD | 0.04 | 0.04 | 0.05① | ||||||
| Malignant tumor | -0.02 | 0.05① | |||||||
| Rheumatic disease | 0.04 |
| 1 | World Health Organization. The World Health Report 2008. Primary Health Cared Now more than ever[M].Geneva:World Health Organization, 2008: 148. |
| 2 | 曹丰, 王亚斌, 薛万国, 等. 中国老年疾病临床多中心报告[J]. 中华老年多器官疾病杂志, 2018, 17(11): 801-808. |
| CAO F, WANG Y B, XUE W G, et al. Clinical multi-centers report of chronic diseases among elderly inpatients in China[J]. Chinese Journal of Multiple Organ Diseases in the Elderly, 2018, 17(11): 801-808. | |
| 3 | 中国高血压防治指南修订委员会, 高血压联盟(中国)中华医学会心血管病学分会中国医师协会高血压专业委员会, 中国医疗保健国际交流促进会高血压分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56. |
| Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, Chinese Medical Doctor Association Hypertension Committee, Hypertension Branch of China International Exchange and Promotive Association for Medical and Health Care, et al. 2018 Chinese guidelines for the management of hypertension[J].Chinese Journal of Cardiovascular Medicine, 2019, 24(1): 24-56. | |
| 4 | 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志, 2021, 13(4): 315-409. |
| Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. Chinese Journal of Diabetes, 2021, 13(4): 315-409. | |
| 5 | 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J]. 中华心血管病杂志, 2016, 44(10): 833-853. |
| Joint Committee Issued Chinese Guideline for the Management of Dyslipidemia. 2016 Chinese guideline for the management of dyslipidemia in adults[J]. Chinese Journal of Cardiovascular Disease, 2016, 44(10): 833-853. | |
| 6 | WILLADSEN T G, SIERSMA V, NICOLAISDÓTTIR D R, et al. Multimorbidity and mortality: a 15-year longitudinal registry-based nationwide Danish population study[J]. J Comorb, 2018, 8(1): 2235042X18804063. |
| 7 | MENOTTI A, MULDER I, NISSINEN A, et al. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: the FINE study (Finland, Italy, Netherlands, Elderly)[J]. J Clin Epidemiol, 2001, 54(7): 680-686. |
| 8 | VOGELI C, SHIELDS A E, LEE T A, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs[J]. J Gen Intern Med, 2007, 22(Suppl 3): 391-395. |
| 9 | ARAMRAT C, CHOKSOMNGAM Y, JIRAPORNCHAROEN W, et al. Advancing multimorbidity management in primary care: a narrative review[J]. Prim Health Care Res Dev, 2022, 23: e36. |
| 10 | SKOU S T, MAIR F S, FORTIN M, et al. Multimorbidity[J]. Nat Rev Dis Primers, 2022, 8: 48. |
| 11 | MCPARLAND C, COOPER M A, LOWE D J, et al. Multimorbidity, disease count, mortality and emergency care use in persons attending the emergency department: a cross-sectional data-linkage study[J]. J Multimorb Comorb, 2022, 12: 26335565221147417. |
| 12 | GARIN N, OLAYA B, PERALES J, et al. Multimorbidity patterns in a national representative sample of the Spanish adult population[J]. PLoS One, 2014, 9(1): e84794. |
| 13 | KIRCHBERGER I, MEISINGER C, HEIER M, et al. Patterns of multimorbidity in the aged population. Results from the KORA-Age study[J]. PLoS One, 2012, 7(1): e30556. |
| 14 | SINHA A, KERKETTA S, GHOSAL S, et al. Multimorbidity and complex multimorbidity in India: findings from the 2017-2018 longitudinal ageing study in India (LASI)[J]. Int J Environ Res Public Health, 2022, 19(15): 9091. |
| 15 | VAN DEN AKKER M, BUNTINX F, METSEMAKERS J F, et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases[J]. J Clin Epidemiol, 1998, 51(5): 367-375. |
| 16 | PEFOYO A J, BRONSKILL S E, GRUNEIR A, et al. The increasing burden and complexity of multimorbidity[J]. BMC Public Health, 2015, 15: 415. |
| 17 | 中国老年保健医学研究会老年内分泌与代谢病分会, 中国毒理学会临床毒理专业委员会. 老年人多重用药安全管理专家共识[J]. 中国全科医学, 2018, 21(29): 3533-3544. |
| Endocrinology and Metabolism Branch of Chinese Association of Geriatric Research, Committee of Clinical Toxicology of Chinese Society of Toxicology. Expert consensus on risk management of polypharmacy in elderly[J]. Chinese General Practice, 2018, 21(29): 3533-3544. | |
| 18 | 黎艳娜, 王艺桥. 我国老年人慢性病共病现状及模式研究[J]. 中国全科医学, 2021, 24(31): 3955-3962, 3978. |
| LI Y N, WANG Y Q. Prevalence and patterns of multimorbidity among Chinese elderly people[J]. Chinese General Practice, 2021, 24(31): 3955-3962, 3978. | |
| 19 | 于普林, 王建业. 老年医学的现状和展望[J]. 中国实用内科杂志, 2011, 31(4): 244-246. |
| YU P L, WANG J Y. Current situation and prospect of geriatric medicine[J].Chinese Journal of Practical Medicine, 2011, 31(4): 244-246. | |
| 20 | 张新卉, 谷雨萌, 王仲言, 等. 三甲医院和社区医院老年慢性病共病现状调查[J]. 临床荟萃, 2021, 36(1): 39-43. |
| ZHANG X H, GU Y M, WANG Z Y, et al.Status investigation of chronic comorbidity status in elderly at tertiary hospitals and community hospitals[J]. Clinical Focus, 2021, 36(1): 39-43. | |
| 21 | 常晶, 侯原平, 吴金玲, 等. 住院老年共病患者5 505例疾病分布特点分析[J]. 中华老年多器官疾病杂志, 2014, 13(4): 251-254. |
| CHANG J, HOU Y P, WU J L, et al. Multi-morbidity patterns in Chinese elderly patients: an analysis of 5 505 in-hospital cases[J]. Chinese Journal of Multiple Organ Diseases in the Elderly, 2014,13(4): 251-254. | |
| 22 | 马珂, 冯玫, 赵瑞敏, 等. 全科医学科住院患者共病情况调查研究[J]. 中国全科医学, 2017, 20(23): 2820-2822. |
| MA K, FENG M, ZHAO R M, et al. Prevalence of comorbidity in inpatientes of department of general practice[J]. Chinese General Practice, 2017, 20(23): 2820-2822. | |
| 23 | ZHAO Y, ATUN R, OLDENBURG B, et al. Physical multimorbidity, health service use, and catastrophic health expenditure by socioeconomic groups in China: an analysis of population-based panel data[J]. Lancet Glob Health, 2020, 8(6): e840-e849. |
| 24 | WANG H H, WANG J J, WONG S Y, et al. Epidemiology of multimorbidity in China and implications for the healthcare system: cross-sectional survey among 162 464 community household residents in Southern China[J]. BMC Med, 2014, 12: 188. |
| 25 | RONG P, CHEN Y, DANG Y, et al. Geographical specific association between lifestyles and multimorbidity among adults in China[J]. PLoS One, 2023, 18(6): e0286401. |
| 26 | DENG X, DONG P, ZHANG L, et al. Health-related quality of life in residents aged 18 years and older with and without disease: findings from the First Provincial Health Services Survey of Hunan, China[J]. BMJ Open, 2017, 7(9): e015880. |
| 27 | GU J, CHAO J, CHEN W, et al. Multimorbidity and health-related quality of life among the community-dwelling elderly: a longitudinal study[J]. Arch Gerontol Geriatr, 2018, 74: 133-140. |
| [1] | LU Xiaobing, YUE Jiang, HE Shengyun, DONG Ying, LU Qing, MA Jing. Effect of intramuscular adipose tissue in the skeletal muscle of thigh on glucose metabolism in male patients with obesity [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1169-1174. |
| [2] | WU Lingheng, CHEN Jianxiong, ZHANG Mengjiao, SHA Lei, CAO Mengmeng, SHEN Cuiqin, DU Lianfang, LI Zhaojun. A study of the effect of suboptimal glycemic control on subclinical myocardial systolic function in patients with T2DM [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(8): 1024-1031. |
| [3] | YAN Yeqing, LIANG Sheng, YANG Bin, ZOU Renjian, MA Yufei, CAI Lisheng, WANG Hui, FU Hongliang. Role of 18F-MD-PSMA PET/CT in initial stage of intermediate and high risk prostate cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(7): 873-881. |
| [4] | CHEN Jiaye, ZHANG Huifeng, LU Wenxian, PENG Daihui. Research progress of brain magnetic resonance imaging related to suicide in bipolar disorder patients [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(7): 939-944. |
| [5] | YANG Haixia, XU Lili, WANG Bocheng, CHEN Minjie. Evaluation of clinical effect of manipulation on masticatory muscle pain guided by MRI [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 540-544. |
| [6] | WANG Wenbo, ZHANG Fangrong, SHI Tingwang, CHEN Yunfeng. Advances in fluorescence imaging of malignant tumors [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(4): 474-479. |
| [7] | ZHANG Chen, GUO Qihui, FAN Qing. Research progress in brain morphological characteristics of obsessive-compulsive disorder [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(4): 480-486. |
| [8] | LIU Chenjun, YIN Bohao, SUN Hui, ZHANG Wei. Application of non-invasive methods of radiology to the osteoporosis [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(3): 385-390. |
| [9] | WU Bing, LI Xiaomin, LIU Siyu, ZHAO Lulu, WU Wen, HAO Yongqiang, AI Songtao. Preliminary application of improved 3D printed pathological section box to assisting stitching pathological images of bone tumor [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 180-187. |
| [10] | CHEN Zixuan, LI Dong, LIU Min. Review of the role of pyroptosis in benign prostatic hyperplasia in old males [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(12): 1569-1576. |
| [11] | YANG lin, WANG Jingbo, HUANG Xiaojuan, REN Jiliang, YUAN ying, TAO Xiaofeng. Exploratory study on detection of cervical lymph node metastasis and extra-nodal extension of oral squamous cell carcinoma using fluorescent probe cMBP-ICG [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1296-1302. |
| [12] | LIU Siyu, WU Bing, LI Xiaomin, ZHAO Lulu, CHEN Jun, AI Songtao. Preliminary exploration of diffusion-weighted imaging in pre-surgical planning of dermatofibrosarcoma protuberans [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(8): 1095-1102. |
| [13] | FENG Baoyi, DONG Tingting, ZHENG Xiaofei, TAO Yong, WU Hao. Comparison of mitochondria and NAD+ level in the murine cochleae of C57BL/6J mice at different ages [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(8): 980-986. |
| [14] | WANG Yuxin, SUN Ruiqi, LIU Jianhua, HE Weina. Development of pH-responsive fluorescent probe for tumor microenvironment imaging [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(7): 875-884. |
| [15] | LAI Xiuxiu, ZHU Qingyan, TAN Jiaqi, YANG Ling, ZHU Yan, ZHOU Gongmin. Clinical study of low dose febuxostat on improving renal function in elderly patients with asymptomatic hyperuricemia [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(7): 885-892. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
